General Information of the Drug (ID: M6APDG04094)
Name
INCB62079
Status
Phase 1/2
TTD Drug ID
D0BE8H
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Fibroblast growth factor receptor 4 (FGFR4)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for INCB62079. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of INCB62079 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). [1], [2]
References
Ref 1 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 2 US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.